Recommended Folic Acid Supplementation for Patients on Methotrexate
All patients receiving low-dose methotrexate should receive at least 5 mg of folic acid per week, with the dose taken at a distance from the methotrexate administration day. This recommendation is strongly supported by multiple international rheumatology guidelines and significantly reduces gastrointestinal and hepatic toxicity without compromising methotrexate efficacy 1.
Evidence-Based Dosing Recommendations
Minimum Weekly Dose: 5 mg
The multinational 3E Initiative, representing expert consensus from international rheumatologists, established at least 5 mg folic acid per week as the minimum recommended dose 1. This recommendation is based on meta-analysis of 788 rheumatoid arthritis patients showing that folic acid supplementation reduces gastrointestinal side effects (OR 0.42) and hepatotoxicity (OR 0.17) without reducing methotrexate efficacy 1.
Alternative Dosing Strategies
For psoriasis patients, dermatology guidelines recommend 1-5 mg daily (except on methotrexate day) 2. The majority of dermatology experts favor routine supplementation at this higher frequency, though some reserve it for patients who develop side effects 2.
The 2020 Joint AAD-NPF guidelines for psoriasis recommend daily folic acid supplementation, given on all days except when methotrexate is administered 3. This approach provides more consistent folate levels throughout the week.
Timing and Administration
Folic acid should be taken at a distance from the methotrexate dose to avoid potential interference with efficacy 3, 4. A practical approach is to administer folic acid on the morning following methotrexate administration 5.
Dose-Response Considerations
When Higher Doses May Be Needed
The evidence suggests that higher folic acid doses (7-35 mg/week) provide greater protection against gastrointestinal side effects compared to 5 mg/week alone 1. However, this benefit was most significant in patients receiving lower methotrexate doses (<10 mg/week) 1.
For hepatotoxicity prevention, 1 mg daily (7 mg/week total) showed significant protective effects regardless of methotrexate dose 1.
When to Increase Supplementation
If patients develop gastrointestinal side effects or early bone marrow toxicity (elevated mean corpuscular volume) while on standard folic acid supplementation, increasing the folic acid dose may be helpful 2. The 2021 ACR guidelines conditionally recommend increased folic/folinic acid doses as a strategy before switching DMARDs in patients with methotrexate intolerance 6.
Important Caveats
Folinic Acid vs. Folic Acid
Folic acid is preferred over folinic acid for routine supplementation 1, 3. While folinic acid at ≤5 mg/week effectively reduces toxicity, doses >5 mg/week were associated with decreased methotrexate efficacy (increased tender and swollen joints) 1. Folic acid is also less expensive with equivalent efficacy 3.
Risk of Excessive Supplementation
Recent evidence raises concerns about very high-dose supplementation. A 2026 study found that folic acid ≥5 mg daily was associated with increased cardiovascular risk in RA patients on methotrexate (adjusted HR 1.34-1.39) 7. This suggests that routine daily supplementation at very high doses may not be beneficial and could be harmful.
Another 2026 trial found that increasing weekly folic acid from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity, though it may improve fatigue in selected patients 8.
Clinical Implementation Algorithm
Start all patients on methotrexate with at least 5 mg folic acid weekly (taken on a different day than methotrexate)
For patients with persistent gastrointestinal symptoms or elevated MCV:
- Increase to 1 mg daily (except methotrexate day) = 6 mg/week total
- Consider split-dose methotrexate or subcutaneous route before further increasing folic acid
For patients with hepatotoxicity concerns:
- Use 1 mg daily dosing (7 mg/week total) which showed strongest hepatoprotective effects 1
Avoid routine daily doses ≥5 mg due to potential cardiovascular risk 7
Monitor for efficacy: If disease control worsens after starting folic acid, ensure folinic acid is not being used at high doses (>5 mg/week) 1
Monitoring Considerations
The absence of folic acid supplementation is a major risk factor for hematologic toxicity 2. Approximately 15-20% of patients in clinical practice do not receive recommended folic acid supplementation despite guidelines 9, representing a significant gap in care that increases toxicity risk.